Oncopeptides raises SEK650M in IPO

Oncopeptides AB (SSE:ONCO) gained SEK2.4 to SEK44.3 in its first day of trading after raising SEK650 million ($72.7 million) through the sale of 14.1 million shares at SEK46 in an IPO underwritten by ABG Sundal Collier, Carnegie Investment Bank and DNB Markets. The offering price values the company at SEK188.4 million ($210.6 million).

According to BioCentury's BCIQ database, Oncopeptides is the fourth Swedish company to go public since 2016, following Wilson Therapeutics AB (SSE:WTX), Xbrane Biopharma AB (SSE:XBRANE) and InDex Pharmaceuticals Holding AB (SSE:INDEX), which raised SEK250 million ($28.7 million) in a September 2016 IPO on the NASDAQ First North exchange (see BioCentury, Oct. 17, 2016)...